IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 224 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,068,965 | -28.9% | 1,993,179 | +10.0% | 0.00% | 0.0% |
| Q2 2023 | $12,758,234 | +61.1% | 1,812,249 | +39.9% | 0.00% | 0.0% |
| Q1 2023 | $7,917,307 | -20.6% | 1,295,795 | -17.0% | 0.00% | 0.0% |
| Q4 2022 | $9,972,566 | -34.1% | 1,560,652 | -1.2% | 0.00% | -33.3% |
| Q3 2022 | $15,135,000 | -14.2% | 1,579,942 | -1.1% | 0.00% | -25.0% |
| Q2 2022 | $17,632,000 | +77.2% | 1,597,097 | +167.2% | 0.00% | +100.0% |
| Q1 2022 | $9,952,000 | -14.2% | 597,687 | -1.6% | 0.00% | 0.0% |
| Q4 2021 | $11,597,000 | -24.4% | 607,502 | -2.4% | 0.00% | -33.3% |
| Q3 2021 | $15,344,000 | -10.6% | 622,214 | -5.7% | 0.00% | 0.0% |
| Q2 2021 | $17,166,000 | -19.8% | 659,706 | -2.4% | 0.00% | -25.0% |
| Q1 2021 | $21,392,000 | -31.5% | 675,709 | +0.3% | 0.00% | -33.3% |
| Q4 2020 | $31,245,000 | +39.3% | 673,399 | -1.1% | 0.01% | +20.0% |
| Q3 2020 | $22,423,000 | +17.7% | 681,180 | -1.8% | 0.01% | 0.0% |
| Q2 2020 | $19,048,000 | -56.9% | 693,911 | -53.0% | 0.01% | -61.5% |
| Q1 2020 | $44,231,000 | +9.5% | 1,477,540 | +1.3% | 0.01% | +44.4% |
| Q4 2019 | $40,390,000 | +50.0% | 1,459,215 | -1.4% | 0.01% | +50.0% |
| Q3 2019 | $26,929,000 | -21.1% | 1,479,616 | +6.3% | 0.01% | -25.0% |
| Q2 2019 | $34,122,000 | +159.7% | 1,391,601 | +0.7% | 0.01% | +166.7% |
| Q1 2019 | $13,139,000 | +9.5% | 1,381,691 | +1.9% | 0.00% | 0.0% |
| Q4 2018 | $12,004,000 | -0.0% | 1,356,387 | +27.1% | 0.00% | 0.0% |
| Q3 2018 | $12,007,000 | -7.9% | 1,067,296 | +4.7% | 0.00% | 0.0% |
| Q2 2018 | $13,043,000 | -11.5% | 1,018,949 | +16.9% | 0.00% | -25.0% |
| Q1 2018 | $14,736,000 | +151.9% | 871,985 | +19.2% | 0.00% | +300.0% |
| Q4 2017 | $5,850,000 | +16.3% | 731,289 | +12.7% | 0.00% | 0.0% |
| Q3 2017 | $5,031,000 | +126.2% | 648,995 | +114.5% | 0.00% | 0.0% |
| Q2 2017 | $2,224,000 | – | 302,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |